Functional gastrointestinal disorders in inflammatory bowel disease: Impact on quality of life and psychological status

Journal of Gastroenterology and Hepatology (Australia)

Volumn 26, Issue 5, 2011, Pages 916-923

  Bryant, Robert V ^a   van Langenberg, Daniel R ^a   Holtmann, Gerald J ^c   Andrews, Jane M ^a,b  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Anxiety; Depression; Functional bowel disorder; Inflammatory bowel disease; Irritable bowel; Quality of life

Indexed keywords

ADULT; AGED; ANXIETY; ARTICLE; COMORBIDITY; CONTROLLED STUDY; CORRELATION ANALYSIS; DEPRESSION; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE ACTIVITY; ENTERITIS; FEMALE; HEALTH SURVEY; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; ULCERATIVE COLITIS;

EID: 79954553840     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2011.06624.x     Document Type: Article

References (49)

1. Drossman DA, Patrick DL, Mitchell CM etal. Health related quality of life in inflammatory bowel disease. Functional status and patient worries and concerns. Dig. Dis. Sci. 1989; 34: 1379-86.
2. Hjortswang H, Strom M, Almer S. Health related quality of life in Swedish patients with ulcerative colitis. Am. J. Gastroenterol. 1998; 93: 2203-11.
3. Irvine EJ, Faegan B, Rochon J etal. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology 1994; 106: 287-96.
4. Simren M, Axelsson J, Gillberg R etal. Health related quality of life in inflammatory bowel disease in remission: the impact of IBS-like symptoms and associated psychological factors. Am. J. Gastroenterol. 2002; 97: 389-96.
5. Addolorato G, Cpristo E, Stafanini GF etal. Inflammatory bowel disease: a study of the association between anxiety and depression, physical morbidity, and nutritional status. Scand. J. Gastroenterol. 1997; 32: 1013-21.
6. Whitehead WE, Crowell MD, Robinson JC etal. Effects of stressful life events on bowel symptoms: subjects with irritable bowel syndrome compared with subjects without bowel dysfunction. Gut 1992; 33: 825-30.
7. Andrews H, Barczak P, Allan RN. Psychiatric illness in patients with inflammatory bowel disease. Gut 1987; 28: 1600-4.
8. Isgar B, Harman M, Kaye MD etal. Symptoms of irritable bowel syndrome in ulcerative colitis in remission. Gut 1983; 24: 190-2.
9. Pezzone MA, Wald A. Functional bowel disorders in inflammatory bowel disease. Gastroenterol. Clin. N. Am. 2002; 31: 347-57.
10. Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology 2006; 130: 1377-90.
11. Farrokhyar F, Marshall JK, Cawdron R etal. Prevalence of functional gastrointestinal disorders in inflammatory bowel disease. Can. J. Gastroenterol. 2001; 15 (Suppl. A): 57A-8A.
12. Minderhoud IM, Oldenburg B, Wismeijer JA etal. IBS-like symptoms in patients with inflammatory bowel disease in remission; relationships with quality of life and coping behaviour. Dig. Dis. Sci. 2004; 49: 469-74.
13. Mikocka-Walus AA, Turnbull DA, Andrews JM etal. The effect of functional gastrointestinal disorders on psychological comorbidity and health related quality of life in patients with inflammatory bowel disease. Aliment. Pharmacol. Ther. 2008; 28: 475-83.
14. Barratt HS, Kalantzis C, Polymeros D etal. Functional symptoms in inflammatory bowel disease and their potential influence in misclassification of clinical status. Alimen. Pharmacol. Ther. 2005; 21: 141-7.
15. Shepherd SJ, Parker SC, Muir JG, Gibson PR. Randomised, placebo-controlled evidence of dietary triggers for abdominal symptoms in patients with irritable bowel syndrome. Clin. Gastroenterol. Hepatol. 2008; 6: 765-71.
16. Rosch W, Liebregts T, Gundermann KJ etal. Phytotherapy for functional dyspepsia: a review of the clinical evidence for the herbal preparation STW-5. Phytomedicine 2006; 13 (Suppl. 5): 113-21.
17. Gearry RB, Irving PM, Barrett JS etal. Reduction of dietary poorly absorbed short-chain carbohydrates (FODMAPs) improves abdominal symptoms in patients with inflammatory bowel disease-a pilot study. J. Crohn Colitis 2009; 3: 8-14.
18. Schepper HU, Man JG, Moreels TG etal. Gastrointestinal sensory and motor disturbances in inflammatory bowel disease-clinical relevance and pathophysiological mechanisms. Aliment. Pharmacol. Ther. 2008; 27: 621-37.
19. Talley NJ. Clinical perspectives: irritable bowel syndrome. Intern. J. Med. 2006; 36: 724-8.
20. Koloski NA, Talley NJ, Boyce PM. A history of abuse in community subjects with irritable bowel syndrome and functional dyspepsia: the role of other psychosocial variables. Digestion 2005; 72: 86-96.
21. Drossman DA. Presidential address: gastrointestinal illness and the biopsychosocial model. Psychosom. Med. 1998; 60: 258-67.
22. Grover M, Herfarth H, Drossman DA. The functional-organic dichotomy: postinfectious irritable bowel syndrome and inflammatory bowel disease-irritable bowel syndrome. Clin. Gastroenterol. Hepatol. 2009; 7: 48-53.
23. Knowles CH, Aziz Q. Visceral hypersensitivity in non-erosive reflux disease. Gut 2008; 57: 674-83.
24. Sostegni R, Daperno M, Scaglione A etal. Crohn's disease: monitoring disease activity. Aliment. Pharmacol. Ther. 2003; 17 (Suppl. 2): 11-7.
25. Harvey RF, Bradshaw JM. A simple index of Crohn's disease activity. Lancet 1980; 1: 514.
26. van Langenberg DR, Lange K, Hetzel DJ etal. Psychiatric comorbidity and prior surgery are associated with poorer outcomes in IBD patients. J. Gastroenterol. Hepatol. 2008; 23 (Suppl. 4): A176.
27. Bertram S, van Langenberg DR, Holtmann G etal. IBD responders and non-responders to a postal questionnaire do not differ greatly: implications for generalizability. J. Gastroenterol. Hepatol. 2008; 23 (Suppl. 4): A178.
28. Irvine EJ, Zhou Q, Thompson AK etal. The Short Inflammatory Bowel Disease Questionnaire. A health related quality of life instrument for community physicians managing inflammatory bowel disease. Am. J. Gastroenterol. 1996; 91: 1571-8.
29. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr. Scand. 1983; 67: 361-70.
30. Bjelland I, Dahl AA, Haug TT etal. The validity of the Hospital Anxiety and Depression Scale: an updated literature review. J. Psychosom. Res. 2002; 52: 69-77.
31. Porcelli P, Leoci C, Guerra V. A prospective study of the relationship between disease activity and psychologic distress in patients with inflammatory bowel disease. Scand. J. Gastroenterol. 1996; 31: 792-6.
32. Talley NJ, Phillips SF, Melton J etal. A patient questionnaire to identify bowel disease. Ann. Intern. Med. 1989; 111: 671-4.
33. Rome III. The functional gastrointestinal disorders. Gastroenterology. 2006; 130: 1377-556.
34. Mikocka-Walus AA, Turnbull DA, Moulding NT etal. Psychological co-morbidity and the complexity of gastrointestinal (GI) symptoms in clinically diagnosed irritable bowel syndrome (IBS) patients. J. Gastroenterol. Hepatol. 2008; 23: 1137-43.
35. Boyce PM, Talley NJ, Burke NA etal. Epidemiology of the functional gastrointestinal disorders diagnosed according to Rome II criteria: an Australian population-based study. Intern. J. Med. 2006; 36: 28-36.
36. Talley NJ. Functional gastrointestinal disorders in 2007 and Rome 3: something new, something borrowed, something objective. Rev. Gastroenterol. Disord. 2007; 7: 97-105.
37. Lomax AE, O'Hara JR, Hyland NP etal. Persistent alterations to enteric neural signalling in the guinea pig colon following the resolution of colitis. Am. J. Physiol. Gastrointest. Liver Physiol. 2007; 292: G482-91.
38. Walker MM, Talley NJ, Prabhaker M etal. Duodenal mastocytosis, eosinophilia and intraepithelial lymphocytosis as possible disease markers in the irritable bowel syndrome and functional dyspepsia. Aliment. Pharmacol. Ther. 2009; 29: 765-73.
39. Talley NJ, Spiller RC. Irritable bowel syndrome: a little understood organic bowel disease? Lancet 2002; 360: 555-64.
40. Marshall JK, Thabane M, Garg AX etal. Incidence and epidemiology of irritable bowel syndrome after a large waterborne outbreak of bacterial dysentery. Gastroenterology. 2006; 131: 445-50.
41. North CA, Hong BA, Alpers DH. Relationship of functional gastrointestinal disorders and psychiatric disorders: implications for treatment. World J. Gastroenterol. 2007; 13: 2020-7.
42. Mawdsley JE, Rampton DS. Psychological stress in IBD: new insights into pathogenic and therapeutic implications. Gut 2005; 54: 1481-91.
43. Collins SM, Barbara G, Vallance B. Stress, inflammation and the irritable bowel syndrome. Can. J. Gastroenterol. 1999; 13 (Suppl. A): 47A-9A.
44. Mikocka-Walus A, Turnbull D, Andrews JM etal. Psychogastroenterology: a call for psychological input in Australian gastroenterology clinics. Intern J Med. 2009; 39: 127-30.
45. Lea R, Whorwell PJ. Health related quality of life in irritable bowel syndrome. Pharmacoeconomics 2001; 19: 643-53.
46. Hammerle CW, Surawicz CM. Updates on the treatment of irritable bowel syndrome. World J. Gastroenterol. 2008; 14: 2639-49.
47. Ford AC, Talley NJ, Schoenfeld PS etal. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut 2009; 58: 367-78.
48. Spiller R, Aziz Q, Creed F etal. Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut 2007; 56: 1770-98.
49. Best WR, Becktel JM, Singleton JW etal. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976; 70: 439-44.